Anaplastic Lymphoma Kinase (ALK) Inhibitors

Small molecule inhibitors of EGFR (epidermal growth factor receptor) have been broadly utilized in lung cancer therapy. A minor subset (3–13 %) of non-small cell lung cancer (NSCLC) has been proven to cause rearrangements in the ALK (anaplastic lymphoma kinase) gene.

In the last decade, research has demonstrated that ALK inhibitors offer considerable advantages in the administration of ALK-positive NSCLC as in comparison to standard chemotherapy. The treatment of patients with advanced NSCLC possessing chromosomal rearrangements of ALK has been transformed by the evolution of Crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET.

Nevertheless, the restricted progression-free survival (PFS), coupled with the rate of advancement in the CNS utilizing Crizotinib for the treatment of NSCLC, have prompted the development of second-generation ALK-inhibitors. These inhibitors, which include Ceritinib and Alectinib, can impede most of the clinically detected ALK mutations that cause resistance to Crizotinib.

A number of new Tyrosine Kinase Inhibitors (TKIs) are at different stages of clinical development for ALK-positive cancers. Many of these agents have activity both in the CNS and in cancers that have developed resistance to Crizotinib. BioVision proudly supplies a broad selection of ALK inhibitors for research.

BioVision Incorporated

BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.

BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 20, 2019 at 12:34 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioVision Incorporated. (2019, June 20). Anaplastic Lymphoma Kinase (ALK) Inhibitors. News-Medical. Retrieved on January 20, 2020 from https://www.news-medical.net/whitepaper/20190603/Anaplastic-Lymphoma-Kinase-(ALK)-Inhibitors.aspx.

  • MLA

    BioVision Incorporated. "Anaplastic Lymphoma Kinase (ALK) Inhibitors". News-Medical. 20 January 2020. <https://www.news-medical.net/whitepaper/20190603/Anaplastic-Lymphoma-Kinase-(ALK)-Inhibitors.aspx>.

  • Chicago

    BioVision Incorporated. "Anaplastic Lymphoma Kinase (ALK) Inhibitors". News-Medical. https://www.news-medical.net/whitepaper/20190603/Anaplastic-Lymphoma-Kinase-(ALK)-Inhibitors.aspx. (accessed January 20, 2020).

  • Harvard

    BioVision Incorporated. 2019. Anaplastic Lymphoma Kinase (ALK) Inhibitors. News-Medical, viewed 20 January 2020, https://www.news-medical.net/whitepaper/20190603/Anaplastic-Lymphoma-Kinase-(ALK)-Inhibitors.aspx.

Other White Papers by this Supplier